Merrimack Pharmaceuticals Stock Gross Profit

MACKDelisted Stock  USD 11.96  0.12  1.01%   
Merrimack Pharmaceuticals fundamentals help investors to digest information that contributes to Merrimack Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Merrimack Stock. The fundamental analysis module provides a way to measure Merrimack Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Merrimack Pharmaceuticals stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Merrimack Pharmaceuticals Company Gross Profit Analysis

Merrimack Pharmaceuticals' Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Gross Profit

 = 

Revenue

-

Cost of Revenue

More About Gross Profit | All Equity Analysis

Current Merrimack Pharmaceuticals Gross Profit

    
  (9.1 M)  
Most of Merrimack Pharmaceuticals' fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Merrimack Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Competition

According to the company disclosure, Merrimack Pharmaceuticals reported (9.1 Million) of gross profit. This is 100.41% lower than that of the Biotechnology sector and 100.96% lower than that of the Health Care industry. The gross profit for all United States stocks is 100.03% higher than that of the company.

Merrimack Gross Profit Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Merrimack Pharmaceuticals' direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Merrimack Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Merrimack Pharmaceuticals by comparing valuation metrics of similar companies.
Merrimack Pharmaceuticals is currently under evaluation in gross profit category among its peers.

Merrimack Fundamentals

About Merrimack Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Merrimack Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Merrimack Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Merrimack Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Other Consideration for investing in Merrimack Stock

If you are still planning to invest in Merrimack Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Merrimack Pharmaceuticals' history and understand the potential risks before investing.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios